June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.The plaintiffs included the Canadian units of Pfizer Inc , AbbVie Corp, Amgen Inc, Bristol Myers Squibb Co, AstraZeneca Plc, Novartis AG and Eli Lilly and Co.